Yazdan Yazdanpanah, Éloi Verrier & Fabien Zoulim
Chairs: Jean-Michel Pawlotsky and Éloi Verrier
HBV cure and RNH joint session
What are the knowledge gaps to cure HBV and HDV infections?
Massimo Levrero, Lyon
Chairs: Christine Neuveut and Guillaume Giraud
Viral chromatin: the role of nucleosome occupancy in cccDNA transcription
Robert Schwartz, New York (20’ + 5’)
Episomal and integrated hepatitis B transcriptome mapping in the liver of CHB patients
Jane McKeating, Oxford (20’ + 5’)
Chairs: Pierre Tonnerre and Hélène Strick-Marchand
HBV specific T cell modulation
Maike Hofmann, Freiburg (20’ + 5’)
HBV specific B cell responses
Lucy Cooper, London (20’ + 5’)
Chairs: Andres Roca and David Durantel
Spatial single-cell omics: new insights into liver diseases.
Bertram Bengsch, Freiburg (20′ + 5′)
Single-cell landscape of the myeloid cell adaptations during liver fibrosis
Moritz Peiseler, Berlin (20′ + 5′)
Heterogeneity of HBV/HDV and immune response distribution in the liver
Maëlle Locatelli (20′ + 5′)
Chairs: Patrick Soussan and Barbara Testoni
Induction of HBV-specific immune responses in immunocompetent humanized mice
Hélène Strick-Marchand, Paris (20′ + 5′)
Development of novel therapeutic vaccine candidates
Anna Kosinska, Munich (20′ + 5′)
Gene and epigenome editing of HBV
Anuj Kumar & Fabien Zoulim, Lyon (20′ + 5′)
New approach to target HDV with antisense oligonucleotides
Julie Lucifora, Lyon (20′ + 5′)
Chairs: Vincent Thibault and Lucia Parlati
Hepatocellular carcinoma risk in a real-life cohort of chronic hepatitis B
Marc Bourlière, Marseille (20′ + 5′)
Immune profiling of patients with CHB and CHD
Upkar Gill, London (20′ + 5′)
Artificial intelligence in cohort studies and clinical trials for CHB and CHD
Anders Boyd, Bern (20′ + 5′)
Chairs: Vincent Leroy and Hélène Fontaine
Treatment endpoints to guide clinical development of novel therapies
Jordan Feld, Toronto (20′ + 5′)
Advances in RNA interference development
Man-Fung Yuen, Hong Kong (20′ + 5′)
An update on Bulevirtide and novel treatments for CHD
Elisabetta Degespari, Milan (20′ + 5′)
Yazdan Yazdanpanah, Éloi Verrier & Fabien Zoulim
Chairs: Jean-Michel Pawlotsky and Éloi Verrier
HBV cure and RNH joint session
Chair Raymond Schinazi
What are the knowledge gaps to cure HBV and HDV infections ?
Massimo Levrero, Lyon
Chairs: Christine Neuveut and Guillaume Giraud
Viral chromatin: the role of nucleosome occupancy in cccDNA transcription
Robert Schwartz, New York
Episomal and integrated hepatitis B transcriptome mapping in the liver of CHB patients
Jane McKeating, Oxford
Chairs: Pierre Tonnerre and Hélène Strick-Marchand
Beyond exhaustion : T cell adaptation in chronic HVB infection
Maike Hofmann, Freiburg
Distinct B cell phenotypes in chronic Hepatitis B precede spontaneous HBsAg clearance
Lucy Cooper, London
Chairs: Andres Roca and David Durantel
Spatial single-cell omics: new insights into liver diseases.
Bertram Bengsch, Freiburg
Single-cell landscape of the myeloid cell adaptations during liver fibrosis
Moritz Peiseler, Berlin
Heterogeneity of HBV/HDV and immune response distribution in the liver
Maëlle Locatelli, Barcelona
Chairs: Patrick Soussan and Barbara Testoni
Induction of HBV-specific immune responses in immunocompetent humanized mice
Hélène Strick-Marchand, Paris
Development of novel therapeutic vaccine candidates
Anna Kosinska, Munich
Gene and epigenome editing of HBV
Anuj Kumar & Fabien Zoulim, Lyon
New approach to target HDV with antisense oligonucleotides
Julie Lucifora, Lyon
Chairs: Vincent Thibault and Lucia Parlati
Hepatocellular carcinoma risk in a real-life cohort of chronic hepatitis B
Marc Bourlière, Marseille
Immune profiling of patients with CHB and CHD
Upkar Gill, London
Artificial intelligence in cohort studies and clinical trials for CHB and CHD
Anders Boyd, Bern
Chairs: Vincent Leroy and Hélène Fontaine
Treatment endpoints to guide clinical development of novel therapies
Jordan Feld, Toronto
Advances in RNA interference development
Man-Fung Yuen, Hong Kong
An update on Bulevirtide and novel treatments for CHD
Elisabetta Degasperi, Milan